The table below shows UroGen Pharma Ltd.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$45.32M
-$42.02M
-$31.73M
-$25.81M
-$24.00M
-$27.40M
Capital expenditure
$54.00K
$44.00K
$0.00
$23.00K
$25.00K
$287.00K
Investing cash flow
-$20.69M
-$25.96M
$13.52M
$6.27M
$13.60M
$15.02M
Dividends paid
-
-
-
-
URGN operating cash flow (10-K history)
UroGen Pharma Ltd. reported operating cash flow of -$162.44M for fiscal year 2025. That is down 67.9% from -$96.77M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from $4.19M (FY 2016) to -$162.44M. Figures come from the company's audited annual reports as filed with the SEC.